Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Dyadic International (Usa) Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 3 distinct examiners and 3 distinct art units, indicating a highly fragmented prosecution landscape where each action is handled by a different individual. The parity between the total actions and the number of examiners suggests that no single reviewer is currently managing multiple files for this company.
MOAZZAMI, NAGHMEH NINA is identified as the busiest examiner for this company. This examiner is responsible for 1 pending office action, which represents a significant portion of the total pending actions for this specific portfolio. Practitioners should note the 1 to 1 ratio between pending actions and distinct examiners. The involvement of multiple art units further indicates that the company's biotechnology research spans several specialized classifications, requiring a prosecution strategy that accounts for varying standards across different administrative groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320558 | USING FUNGAL CONSTRUCTS TO PRODUCE VIRAL PROTEIN ANTIGENS | ALAM, DANYAL HASSAN | — |
| 17924927 | MODIFIED FILAMENTOUS FUNGI FOR PRODUCTION OF EXOGENOUS PROTEINS | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17924927 | MODIFIED FILAMENTOUS FUNGI FOR PRODUCTION OF EXOGENOUS PROTEINS | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18320558 | USING FUNGAL CONSTRUCTS TO PRODUCE VIRAL PROTEIN ANTIGENS | ALAM, DANYAL HASSAN | 1672 | §102§103§112 | Non-Final OA | — | Pending | May 19, 2023 |
| 17924927 | MODIFIED FILAMENTOUS FUNGI FOR PRODUCTION OF EXOGENOUS PROTEINS | LEITH, NANCY J | 1636 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDyadic International (Usa) Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Danyal Hassan Alam has the most, with 1 of Dyadic International (Usa) Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
